Cited by 1,076Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Open access

Larochelle, Marc R., Bernson, Dana, Land, Thomas, Stopka, Thomas J., Wang, Na, Xuan, Ziming, Bagley, Sarah M., Liebschutz, Jane M., Walley, Alexander Y.·2018·Annals of Internal Medicine

DOI 10.7326/m17-3107PMC PMC6387681

Open this paper in CoChat — free account

Abstract

Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective: To identify MOUD use after opioid overdose and its association with all-cause and opioid-related mortality. Design: Retrospective cohort study. Setting: 7 individually linked data sets from Massachusetts government agencies. Participants: 17 568 Massachusetts adults without cancer who survived an opioid overdose between 2012 and 2014. Measurements: Three types of MOUD were examined: methadone maintenance treatment (MMT), buprenorphine, and naltrexone. Exposure to MOUD was identified at monthly intervals, and persons were considered exposed through the month after last receipt. A multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality. Results: In the 12 months after a nonfatal overdose, 2040 persons (11%) enrolled in MMT for a median of 5 months (interquartile range, 2 to 9 months), 3022 persons (17%) received buprenorphine for a median of 4 months (interquartile range, 2 to 8 months), and 1099 persons (6%) received naltrexone for a median of 1 month (interquartile range, 1 to 2 months). Among the entire cohort, all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person-years and opioid-related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. Compared with no MOUD, MMT was associated with decreased all-cause mortality (adjusted hazard ratio [AHR], 0.47 [CI, 0.32 to 0.71]) and opioid-related mortality (AHR, 0.41 [CI, 0.24 to 0.70]). Buprenorphine was associated with decreased all-cause mortality (AHR, 0.63 [CI, 0.46 to 0.87]) and opioid-related mortality (AHR, 0.62 [CI, 0.41 to 0.92]). No associations between naltrexone and all-cause mortality (AHR, 1.44 [CI, 0.84 to 2.46]) or opioid-related mortality (AHR, 1.42 [CI, 0.73 to 2.79]) were identified. Limitation: Few events among naltrexone recipients preclude confident conclusions. Conclusion: A minority of opioid overdose survivors received MOUD. Buprenorphine and MMT were associated with reduced all-cause and opioid-related mortality. Primary Funding Source: National Center for Advancing Translational Sciences of the National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7326/m17-3107

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 913
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., Davoli, M., & Breen, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209 · Cited by 536

Flagged first, then by citations

Show all 38 references

4 of the 38 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 1,000

Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine
Calcaterra, S. L., Martín, M., Bottner, R., Englander, H. L., Weinstein, Z., Weimer, M. B., Lambert, E., & Herzig, S. J. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12893 · Cited by 58
Court personnel attitudes towards medication-assisted treatment: A state-wide survey
Andraka‐Christou, B., Gabriel, M. H., Madeira, J. L., & Silverman, R. D. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.011 · Cited by 56
Association between mortality rates and medication and residential treatment after in‐patient medically managed opioid withdrawal: a cohort analysis
Walley, A. Y., Lodi, S., Li, Y., Bernson, D., Babakhanlou‐Chase, H., Land, T. G., & Larochelle, M. R. (2020) · Addiction · doi:10.1111/add.14964 · Cited by 56
Self-citation
Opioid Use Disorder: Medical Treatment Options.
Coffa, D. A., & Snyder, H. R. (2019) · PubMed · Cited by 55
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
Lim, J., Farhat, I., Douros, A., & Panagiotoglou, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266142 · Cited by 59
Opioid use disorder: current trends and potential treatments
Lee, Y. K., Gold, M. S., Blum, K., Thanos, P. K., Hanna, C., & Fuehrlein, B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1274719 · Cited by 59
User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial
Melnick, E. R., Nath, B., Dziura, J. D., Casey, M. F., Jeffery, M. M., Paek, H., Soares, W. E., Hoppe, J. A., Rajeevan, H., Li, F., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069271 · Cited by 52
“How will I get my next week's script?” Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic
Krawczyk, N., Bunting, A. M., Frank, D., Arshonsky, J., Gu, Y., Friedman, S. R., & Bragg, M. A. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103140 · Cited by 52
Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers
Hu, T., Snider-Adler, M., Nijmeh, L., & Pyle, A. (2019) · Canadian Journal of Emergency Medicine · doi:10.1017/cem.2019.24 · Cited by 52
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder
Haffajee, R. L., Andraka‐Christou, B., Attermann, J., Cupito, A., Buche, J., & Beck, A. J. (2020) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-020-00312-3 · Cited by 51
Nicotine and Opioids: a Call for Co-treatment as the Standard of Care
Morris, C. D., & Garver‐Apgar, C. E. (2020) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-020-09712-6 · Cited by 51
Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample
Krawczyk, N., Garrett, B. A., Ahmad, N. J., Patel, E., Solomon, K. T., Stuart, E. A., & Saloner, B. K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108512 · Cited by 51
Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries
Samples, H., Nowels, M., Williams, A. R., Olfson, M., & Crystal, S. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.01.037 · Cited by 51
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
Thakrar, A. P., Christine, P. J., Siaw-Asamoah, A., Spadaro, A., Faude, S., Snider, C. K., Delgado, M. K., Lowenstein, M., Kampman, K. M., Perrone, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.35895 · Cited by 51
Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
D’Onofrio, G., Edelman, E. J., Hawk, K. F., Chawarski, M. C., Pantalon, M. V., Owens, P. H., Martel, S. H., Rothman, R. E., Saheed, M. O., Schwartz, R. P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.5439 · Cited by 50
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
Meinhofer, A., Williams, A. R., Johnson, P., Schackman, B. R., & Bao, Y. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.07.010 · Cited by 50
Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada
Young, S., Kolla, G., McCormack, D., Campbell, T. J., Leece, P., Strıke, C., Srivastava, A., Antoniou, T., Bayoumi, A. M., & Gomes, T. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103601 · Cited by 50
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers
Stopka, T. J., Rottapel, R. E., Ferguson, W. J., Pivovarova, E., Toro-Mejías, L. M. D., Friedmann, P. D., & Evans, E. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103803 · Cited by 49
Self-citation
Canadian Guidelines on Opioid Use Disorder Among Older Adults
Rieb, L. M., Samaan, Z., Furlan, A. D., Rabheru, K., Feldman, S., Hung, L., Budd, G., & Coleman, D. (2020) · Canadian Geriatrics Journal · doi:10.5770/cgj.23.420 · Cited by 55
Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries
Mark, T. L., Parish, W. J., & Zarkin, G. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3132 · Cited by 49
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder
Lin, L. A., Zhang, L., Kim, H. M., & Frost, M. C. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21111141 · Cited by 48
A Population Health Approach to America's Opioid Epidemic
Salmond, S. W., & Allread, V. (2019) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000521 · Cited by 48
Management of Opioid Misuse and Opioid Use Disorders Among Youth
Robinson, C. A., & Wilson, J. D. (2020) · PEDIATRICS · doi:10.1542/peds.2019-2056c · Cited by 48
Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study
Kim, J., Fine, D. R., Li, L., Kimmel, S. D., Ngo, L. H., Suzuki, J., Price, C. N., Ronan, M. V., & Herzig, S. J. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003247 · Cited by 48
Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder
Lowenstein, M., Perrone, J., Xiong, R. A., Snider, C. K., O’Donnell, N., Hermann, D., Rosin, R. M., Dees, J., McFadden, R. B., Khatri, U. G., et al. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.10.012 · Cited by 48
Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services
Carroll, G. G., Solomon, K. T., Heil, J., Saloner, B. K., Stuart, E. A., Patel, E., Greifer, N., Salzman, M., Murphy, E. M., Baston, K., et al. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.07.006 · Cited by 47
Predictors for 30-Day and 90-Day Hospital Readmission Among Patients With Opioid Use Disorder
Moreno, J. L., Wakeman, S. E., Duprey, M. S., Roberts, R. J., Jacobson, J. S., & Devlin, J. W. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000499 · Cited by 47
Mortality Following Nonfatal Opioid and Sedative/Hypnotic Drug Overdose
Goldman-Mellor, S. J., Olfson, M., Lidón‐Moyano, C., & Schoenbaum, M. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.02.012 · Cited by 46
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
Barocas, J. A., Savinkina, A. A., Adams, J. W., Jawa, R., Weinstein, Z., Samet, J. H., & Linas, B. P. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00248-6 · Cited by 49
Overdose Prevention Through Medical Treatment of Opioid Use Disorders
Volkow, N. D., & Wargo, E. M. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1397 · Cited by 47
Treatment of Opioid Use Disorder in the Acute Hospital Setting: a Critical Review of the Literature (2014–2019)
Weimer, M. B., Morford, K. L., & Donroe, J. H. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00267-x · Cited by 46
Identifying Opioid Use Disorder in the Emergency Department: Multi-System Electronic Health Record–Based Computable Phenotype Derivation and Validation Study
Chartash, D., Paek, H., Dziura, J. D., Ross, B. K., Nogee, D., Boccio, E., Hines, C., Schott, A. M., Jeffery, M. M., Patel, M. D., et al. (2019) · JMIR Medical Informatics · doi:10.2196/15794 · Cited by 44
Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine
Strayer, R. J., Hawk, K. F., Hayes, B. D., Herring, A. A., Ketcham, E. M., LaPietra, A. M., Lynch, J. J., Motov, S. M., Repanshek, Z. D., Weiner, S. G., et al. (2020) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.12.034 · Cited by 47
Identification and Management of Opioid Use Disorder in Primary Care: an Update
Donroe, J. H., Bhatraju, E. P., Tsui, J. I., & Edelman, E. J. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01149-0 · Cited by 46
A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs
Hawk, K. F., Grau, L. E., Fiellin, D. A., Chawarski, M. C., O’Connor, P. G., Cirillo, N., Breen, C., & D’Onofrio, G. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14197 · Cited by 46
Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting
Cisewski, D. H., Santos, C. D., Koyfman, A., & Long, B. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.10.013 · Cited by 47
Patterns and history of prescription drug use among opioid-related drug overdose cases in British Columbia, Canada, 2015–2016
Smolina, K., Crabtree, A., Chong, M., Zhao, B., Park, M., Mill, C., & Schütz, C. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.09.019 · Cited by 49
Strengths and weaknesses of existing data sources to support research to address the opioids crisis
Smart, R., Kase, C., Taylor, E. A., Lumsden, S., Smith, S. R., & Stein, B. D. (2019) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2019.101015 · Cited by 48
Big data and predictive modelling for the opioid crisis: existing research and future potential
Bharat, C., Hickman, M., Barbieri, S., & Degenhardt, L. J. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00058-3 · Cited by 47
Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio
Young, A. M., Brown, J. L., Hunt, T., Martinez, L. S. S., Chandler, R. K., Oga, E. A., Winhusen, T. M., Baker, T. J., Battaglia, T. A., Bowers-Sword, R., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059328 · Cited by 46
Adherence to buprenorphine: An analysis of prescription drug monitoring program data
Pizzicato, L. N., Hom, J. K., Sun, M., Johnson, C. C., & Viner, K. M. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108317 · Cited by 44
Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting
Spadaro, A., Long, B., Koyfman, A., & Perrone, J. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.05.013 · Cited by 44
Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States
Davis, C. S., & Carr, D. H. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.07.006 · Cited by 43
Interrupted Time Series of User‐centered Clinical Decision Support Implementation for Emergency Department–initiated Buprenorphine for Opioid Use Disorder
Holland, W. C., Nath, B., Li, F., Maciejewski, K. R., Paek, H., Dziura, J., Rajeevan, H., Lu, C. C., Katsovich, L., D’Onofrio, G., et al. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14002 · Cited by 41
Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review
Kennedy, A. J., Wessel, C. B., Levine, R. E., Downer, K., Raymond, M. B., Osakue, D., Hassan, I. F., Merlin, J. S., & Liebschutz, J. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06448-z · Cited by 42
Self-citation
Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term SM) communities study
Chandler, R. K., Nunes, E. V., Tan, S., Freeman, P. R., Walley, A. Y., Lofwall, M. R., Oga, E. A., Glasgow, L., Brown, J. L., Fanucchi, L. C., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109804 · Cited by 41
Self-citation
Civil commitment experiences among opioid users
Christopher, P. P., Anderson, B. J., & Stein, M. D. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.10.001 · Cited by 41
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine
Vorspan, F., Hjelmström, P., Simon, N., Benyamina, A., Dervaux, A., Brousse, G., Jamain, T., Kosim, M., & Rolland, B. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1649252 · Cited by 41
A novel social work approach to emergency department buprenorphine induction and warm hand-off to community providers
Kelly, T., Hoppe, J. A., Zuckerman, M. D., Khoshnoud, A., Sholl, B., & Heard, K. J. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.12.038 · Cited by 41
Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review
Peckham, A. M., & Young, E. H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa503 · Cited by 41
Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department
Martin, A., Butler, K., Chavez, T. J., Herring, A. A., Wakeman, S. E., Hayes, B. D., & Raja, A. S. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.7.46079 · Cited by 41
Effect of Inpatient Medication-Assisted Therapy on Against-Medical-Advice Discharge and Readmission Rates
Wang, S. J., Wade, E., Towle, J., Hachey, T., Rioux, J., Samuels, O., Bonner, C., Kirkpatrick, C. M., O'Loughlin, S., & Foster, K. J. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.04.025 · Cited by 40
Are x‐waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x‐waiver trainings
Gordon, A. J., Kenny, M. E., Dungan, M. T., Gustavson, A. M., Kelley, A. T., Jones, A. L., Hawkins, E. J., Frank, J. W., Danner, A. N., Liberto, J. C., et al. (2022) · American Journal on Addictions · doi:10.1111/ajad.13260 · Cited by 40
Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines
Calcaterra, S. L., Bottner, R., Martín, M., Englander, H. L., Weinstein, Z., Weimer, M. B., Lambert, E., Ronan, M. V., Huerta, S., Zaman, T., et al. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12908 · Cited by 41
Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012–2014
Chatterjee, A., Larochelle, M. R., Xuan, Z., Wang, N., Bernson, D., Silverstein, M., Hadland, S. E., Land, T. G., Samet, J. H., Walley, A. Y., et al. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.09.020 · Cited by 40
Self-citation
Individual and county-level variation in outcomes following non-fatal opioid-involved overdose
Lowder, E. M., Amlung, J., & Ray, B. R. (2020) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2019-212915 · Cited by 42
The Impact of Access to Addiction Specialist on Attitudes, Beliefs and Hospital-Based Opioid Use Disorder Related Care: A Survey of Hospitalist Physicians
Calcaterra, S. L., Binswanger, I. A., Edelman, E. J., McNair, B. K., Wakeman, S. E., & O’Connor, P. G. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1748169 · Cited by 41
Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis
Xu, K. Y., Borodovsky, J. T., Presnall, N. J., Mintz, C. M., Hartz, S. M., Bierut, L. J., & Grucza, R. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081174 · Cited by 41
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose
Bagley, S. M., Larochelle, M. R., Xuan, Z., Wang, N., Patel, A. A., Bernson, D., Silverstein, M., Hadland, S. E., Land, T. G., Samet, J. H., et al. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.030 · Cited by 39
Self-citation
Rewarding recovery: the time is now for contingency management for opioid use disorder
Proctor, S. L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2068805 · Cited by 39
Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016
Askari, M. S., Martins, S. S., & Mauro, P. M. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108028 · Cited by 39
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness
Han, B. H., Doran, K. M., & Krawczyk, N. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108504 · Cited by 41
Emergency Department Peer Support Program and Patient Outcomes After Opioid Overdose
Treitler, P. C., Crystal, S., Cantor, J. C., Chakravarty, S., Kline, A., Morton, C. M., Powell, K. G., Borys, S. V., & Cooperman, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3614 · Cited by 38
User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial
Melnick, E. R., Jeffery, M. M., Dziura, J. D., Mao, J. A., Hess, E. P., Platts‐Mills, T. F., Solad, Y., Paek, H., Martel, S. H., Patel, M. D., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028488 · Cited by 38
The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose
Karmali, R. N., Ray, G. T., Rubinstein, A. L., Sterling, S., Weisner, C. M., & Campbell, C. I. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107923 · Cited by 38
Providing Incentive for Emergency Physician X-Waiver Training: An Evaluation of Program Success and Postintervention Buprenorphine Prescribing
Foster, S. D., Lee, K., Edwards, C., Pelullo, A., Khatri, U. G., Lowenstein, M., & Perrone, J. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.02.020 · Cited by 39
Chronic heroin use disorder and the brain: Current evidence and future implications
Tolomeo, S., Steele, J. D., Ekhtiari, H., & Baldacchino, A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110148 · Cited by 45
Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder
DeRonne, B., Wong, K. R., Schultz, E., Jones, E., & Krebs, E. E. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa405 · Cited by 41
Modeling buprenorphine reduction of fentanyl-induced respiratory depression
Olofsen, E., Algera, M. H., Moss, L. M., Dobbins, R. L., Groeneveld, G. J., van Velzen, M., Niesters, M., Dahan, A., & Laffont, C. M. (2022) · JCI Insight · doi:10.1172/jci.insight.156973 · Cited by 38
Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis
Roy, P. J., Suda, K. J., Luo, J., Lee, M., Anderton, J., Olejniczak, D. M., & Liebschutz, J. M. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104381 · Cited by 37
Self-citation
Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series
Peckham, A. M., Kehoe, L. G., Gray, J. R., & Wakeman, S. E. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108316 · Cited by 37
Treatment provider perceptions of take-home methadone regulation before and during COVID-19
Madden, E. F., Christian, B. T., Lagisetty, P., Ray, B. R., & Sulzer, S. H. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109100 · Cited by 37
The relationship between police contacts for drug use-related crime and future arrests, incarceration, and overdoses: a retrospective observational study highlighting the need to break the vicious cycle
Zhang, A., Balles, J. A., Nyland, J. E., Nguyen, T. H., White, V. M., & Zgierska, A. E. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00652-2 · Cited by 38
Trends in opioid use disorder and overdose among opioid‐naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014
Burke, L. G., Zhou, X., Boyle, K. L., Orav, E. J., Bernson, D., Hood, M., Land, T., Bharel, M., & Frakt, A. B. (2020) · Addiction · doi:10.1111/add.14867 · Cited by 35
Self-citation
Characteristics of post-overdose public health-public safety outreach in Massachusetts
Formica, S. W., Waye, K. M., Benintendi, A., Yan, S., Bagley, S. M., Beletsky, L. A., Carroll, J. J., Xuan, Z., Rosenbloom, D., Apsler, R., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108499 · Cited by 36
Self-citation
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment
Nunes, E. V., Scodes, J. M., Pavlicová, M., Lee, J. D., Novo, P., Campbell, A. N. C., & Rotrosen, J. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060816 · Cited by 36
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
Xu, K. Y., Mintz, C. M., Presnall, N. J., Bierut, L. J., & Grucza, R. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11363 · Cited by 36
Opioid Harm Reduction: A Scoping Review of Physician and System-Level Gaps in Knowledge, Education, and Practice
Gugala, E., Briggs, O., Moczygemba, L. R., Brown, C. M., & Hill, L. G. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2060423 · Cited by 35
Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities
Pytell, J. D., Sharfstein, J. M., & Olsen, Y. K. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.5731 · Cited by 35
Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment
Yedinak, J. L., Goedel, W. C., Paull, K., Lebeau, R., Krieger, M. S., Thompson, C., Buchanan, A. L., Coderre, T., Boss, R., Rich, J. D., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002963 · Cited by 35
Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use
Wen, H., Soni, A., Hollingsworth, A. J., Freedman, S. M., Benitez, J. A., Simon, K. I., & Saloner, B. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0473 · Cited by 35
Age disparities in six-month treatment retention for opioid use disorder
Mintz, C. M., Presnall, N. J., Sahrmann, J. M., Borodovsky, J. T., Glaser, P. E. A., Bierut, L. J., & Grucza, R. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108130 · Cited by 35
Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city
Spinelli, M. A., Hessol, N. A., Schwarcz, S. K., Hsu, L. C., Parisi, M. K., Pipkin, S. S., Scheer, S., Havlir, D. V., & Buchbinder, S. (2019) · AIDS · doi:10.1097/qad.0000000000002287 · Cited by 33
The substance use intervention team: A hospital-based intervention and outpatient clinic to improve care for patients with substance use disorders
Tran, T. H., Swoboda, H., Perticone, K., Ramsey, E., Thompson, H. M., Hill, K., & Karnik, N. S. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa408 · Cited by 34
Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl
Suen, L. W., Chiang, A. Y., Jones, B. L. H., Soran, C. S., Geier, M., Snyder, H. R., Neuhaus, J. M., Myers, J. J., Knight, K. R., Bazazi, A. R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.56253 · Cited by 33
Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment
Amiri, S., Lutz, R. B., McDonell, M. G., Roll, J. M., & Amram, O. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1620261 · Cited by 33
A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation
Wakeman, S. E., Kane, M. T., Powell, E. A., Howard, S., Shaw, C. J., Kehoe, L., Rosen, J. B., Quinlan, J., & Regan, S. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1846664 · Cited by 33
The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill
Nguyen, T. D., Muench, U., Andraka‐Christou, B., Simon, K. I., Bradford, W. D., & Spetz, J. (2021) · Medical Care Research and Review · doi:10.1177/10775587211004311 · Cited by 33
Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020
Cantor, J., Powell, D., Kofner, A., & Stein, B. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109107 · Cited by 33
Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers
Calcaterra, S. L., Lockhart, S., Callister, C., Hoover, K., & Binswanger, I. A. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07305-3 · Cited by 35
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention
Drainoni, M., Knudsen, H. K., Adams, K., Andrews-Higgins, S., Auritt, V., Back, S., Barkowski, L. K., Batty, E. J., Behrooz, M. R., Bell, S., et al. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108731 · Cited by 33
Treatment Experiences Among People Who Use Opioids: A Social Ecological Approach
Kahn, L. S., Wozniak, M., Doscher, T., Moore, C., & Vest, B. M. (2022) · Qualitative Health Research · doi:10.1177/10497323221104315 · Cited by 33
Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs
Suzuki, J., Johnson, J. A., Montgomery, M. W., Hayden, M. C., Price, C. N., Solomon, D. A., Liebschutz, J. M., Schnipper, J. L., & Weiss, R. D. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000572 · Cited by 32
Self-citation
Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use
Jacobson, N. A., Horst, J., Wilcox-Warren, L., Toy, A., Knudsen, H. K., Brown, R., Haram, E., Madden, L. M., & Molfenter, T. D. (2020) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-020-09706-4 · Cited by 32
Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting
O’Gurek, D. T., Jatres, J., Gibbs, J., Latham, I., Udegbe, B., & Reeves, K. A. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108342 · Cited by 32
“Sick and tired of being sick and tired”: Exploring initiation of medications for opioid use disorder among people experiencing homelessness
Swartz, N., Adnan, T., Peréa, F. C., Baggett, T. P., & Chatterjee, A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108752 · Cited by 32
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis
Kitchen, S. A., Campbell, T. J., Men, S., Bozinoff, N., Tadrous, M., Antoniou, T., Wyman, J., Werb, D., Munro, C., & Gomes, T. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103644 · Cited by 32
Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program
Ward, K., Scheim, A. I., Wang, J., Cocchiaro, B. F., Singley, K. J., & Roth, A. M. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100055 · Cited by 32
Negative attitudes about medications for opioid use disorder among criminal legal staff
Moore, K. E., Siebert, S. L., Kromash, R., Owens, M. D., & Allen, D. C. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100056 · Cited by 32
Commentary Article: Opioid use Disorder Cascade of Care Framework Design: A Roadmap
Williams, A. R., Johnson, K., Parks, C. L., Reif, S., Socias, M. E., Henry, B. F., Neighbors, C. J., Gordon, A. J., Horgan, C. M., Nosyk, B., et al. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2074604 · Cited by 33

Authors: Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y.
Affiliations: Boston University (US)
Massachusetts Department of Public Health (US)
Tufts University (US)
ORCID: Larochelle, Marc R.
Bernson, Dana
Stopka, Thomas J.
Wang, Na
Xuan, Ziming
Bagley, Sarah M.
Liebschutz, Jane M.
Walley, Alexander Y.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2018-08-07
Volume: 169
Issue: 3
Pages: 137-145
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/m17-3107
PMC: PMC6387681
OpenAlex: W2808907017
Cited by: 1,076
References: 38
Citations by year: 2026: 99 · 2025: 140 · 2024: 161 · 2023: 133 · 2022: 134 · 2021: 157 · 2020: 117 · 2019: 113 · 2018: 21
FWCI: 97.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001430)
National Institute on Drug Abuse (K23DA042168)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: opioid use disorder, medication-assisted treatment, methadone maintenance treatment, buprenorphine, naltrexone, opioid-related deaths, all-cause mortality, opioid overdose prevention
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Massachusetts, Methadone, Middle Aged, Mortality, Naltrexone, Opioid-Related Disorders, Retrospective Studies, Proportional Hazards Models, Young Adult, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks